Biotech companies court venture capitalists

Thirty companies http://www.rmlic.com/presenters.html from Colorado, Arizona, Utah, New Mexico, Wyoming and Montana took turns marketing themselves as part of the inaugural Rocky Mountain Life Science Investor Conference http://www.rmlic.com/.

The event attracted 25 venture capital companies, two-thirds of which were from out of state, said John Collar, chief executive of the Colorado BioScience Association, co-sponsor of the conference.

By Andy Vuong
The Denver Post

Full Story: http://www.denverpost.com/ci_13362212

***

Ligocyte

LigoCyte Pharmaceuticals, Inc. is a private, biopharmaceutical company focused on the development of innovative vaccine products
based on the company’s proprietary virus-like particle platform technology. LigoCyte’s lead candidate recently completed a Phase
I clinical trial for the prevention of norovirus, a ubiquitous and prostrating illness characterized by a fever, vomiting and diarrhea.
LigoCyte also has a novel influenza vaccine in preclinical development that has, notably, demonstrated protection across multiple
influenza subtypes with a single VLP antigen. Incorporated in 1998, LigoCyte has 45 employees and is located in Bozeman, Montana.

http://www.ligocyte.com/